查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1386383

登革热疫苗市场报告：2030 年趋势、预测与竞争分析

Dengue Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

登革热疫苗趋势与预测

预计到 2030 年，全球登革热疫苗市场将达到 11 亿美元，2024 年至 2030 年年复合成长率为 12.1%。该市场的主要驱动因素是登革热疫情日益严重以及全球疫苗开发的研发活动不断增加。全球登革热疫苗市场的未来看起来充满希望，医院、居家医疗和专科诊所市场都有机会。

登革热疫苗市场洞察

Lucintel 预测，抗过敏药物在预测期内将出现最高增长，因为它们被广泛用于治疗和预防过敏反应，例如登革热疫苗接种后发生的过敏反应。

由于免疫接种等医疗保健服务的增加、人们对预防保健的兴趣日益浓厚以及对更高品质医疗保健服务的需求，医院将继续成为市场中最大的细分市场。

由于政府为改善该地区的医疗基础设施支出增加，预计亚太地区在预测期内将出现最高的成长。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球登革热疫苗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球登革热疫苗市场趋势（2018-2023）与预测（2024-2030）
  • 按类型分類的全球登革热疫苗市场
    • 减毒活病毒疫苗
    • 活病毒疫苗
    • 灭活疫苗
    • 亚单位疫苗
    • 核酸疫苗
  • 按治疗分類的全球登革热疫苗市场
    • 利尿剂
    • 抗过敏剂
    • 血液稀释剂
    • 其他的
  • 按配销通路分類的全球登革热疫苗市场
    • 医院药房
    • 线上药房
    • 零售药房
  • 全球登革热疫苗市场（依最终用途）
    • 医院
    • 居家护理
    • 专科诊所
    • 其他的

第4章2018-2030年分地区市场趋势及预测分析

  • 全球登革热疫苗市场区域分布
  • 北美登革热疫苗市场
  • 欧洲登革热疫苗市场
  • 亚太登革热疫苗市场
  • 其他区域登革热疫苗市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 全球登革热疫苗市场成长机会（按类型）
    • 全球登革热疫苗市场按治疗方法的成长机会
    • 全球登革热疫苗市场成长机会（按配销通路）
    • 全球登革热疫苗市场成长机会（依最终用途）
    • 全球登革热疫苗市场成长机会（按地区）
  • 全球登革热疫苗市场的新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球登革热疫苗市场产能
    • 全球登革热疫苗市场的合併、收购和合资企业
    • 认证和许可

第7章主要企业概况

  • Mylan
  • BIO-MED
  • Teva Pharmaceutical
  • Sanofi
  • Novartis
  • GSK
  • F. Hoffmann-La Roche
简介目录

Dengue Vaccine Trends and Forecast

The future of the global dengue vaccine market looks promising with opportunities in the hospital, homecare, and specialty clinic markets. The global dengue vaccine market is expected to reach an estimated $1.1 billion by 2030 with a CAGR of 12.1% from 2024 to 2030. The major drivers for this market are escalating prevalence of dengue fever and rising R&D acitivities for vaccine development across the globe.

A more than 150-page report is developed to help in your business decisions.

Dengue Vaccine by Segment

The study includes a forecast for the global dengue vaccine by type, treatment, distribution channel, end use, and region.

Dengue Vaccine Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Live Attenuated Vaccine
  • Chimeric Live Attenuated Vaccine
  • Inactivated Vaccine
  • Subunit Vaccine
  • Nucleic Acid Based Vaccine

Dengue Vaccine Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Diuretic
  • Anti-Allergic
  • Blood Thinners
  • Others

Dengue Vaccine Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Dengue Vaccine Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Dengue Vaccine Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Dengue Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies dengue vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the dengue vaccine companies profiled in this report include-

  • Mylan
  • BIO-MED
  • Teva Pharmaceutical
  • Sanofi
  • Novartis
  • GSK
  • F. Hoffmann-La Roche

Dengue Vaccine Market Insights

Lucintel forecasts that anti-allergic is expected to witness highest growth over the forecast period due to its significant use to treat and prevent allergic reactions, such as those occur after a dengue vaccination.

Within this market, hospital will remain the largest segment due to increasing healthcare services including immunizations and growing focus towards preventative care and need for higher-quality healthcare services.

APAC is expected to witness highest growth over the forecast period due to rising government expenditure for development of better healthcare infrastructures in the region.

Features of the Global Dengue Vaccine Market

Market Size Estimates: Dengue vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Dengue vaccine market size by various segments, such as by type, treatment, distribution channel, end use, and region in terms of ($B).

Regional Analysis: Dengue vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, treatments, distribution channels, end uses, and regions for the dengue vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the dengue vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the dengue vaccine market size?

Answer: The global dengue vaccine market is expected to reach an estimated $1.1 billion by 2030.

Q.2 What is the growth forecast for dengue vaccine market?

Answer: The global dengue vaccine market is expected to grow with a CAGR of 12.1% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the dengue vaccine market?

Answer: The major drivers for this market are escalating prevalence of dengue fever and rising R&D acitivities for vaccine development across the globe.

Q4. What are the major segments for dengue vaccine market?

Answer: The future of the dengue vaccine market looks promising with opportunities in the hospital, homecare, and specialty clinic markets.

Q5. Who are the key dengue vaccine market companies?

Answer: Some of the key dengue vaccine companies are as follows:

  • Mylan
  • BIO-MED
  • Teva Pharmaceutical
  • Sanofi
  • Novartis
  • GSK
  • F. Hoffmann-La Roche

Q6. Which dengue vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that anti-allergic is expected to witness highest growth over the forecast period due to its significant use to treat and prevent allergic reactions, such as those occur after a dengue vaccination.

Q7. In dengue vaccine market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness highest growth over the forecast period due to rising government expenditure for development of better healthcare infrastructures in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the dengue vaccine market by type (live attenuated vaccine, chimeric live attenuated vaccine, inactivated vaccine, subunit vaccine, and nucleic acid based vaccine), treatment (diuretic, anti-allergic, blood thinners, and others), distribution channel (hospital pharmacy, online pharmacy, and retail pharmacy), end use (hospitals, homecare, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Dengue Vaccine Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Dengue Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Dengue Vaccine Market by Type
    • 3.3.1: Live Attenuated Vaccine
    • 3.3.2: Chimeric Live Attenuated Vaccine
    • 3.3.3: Inactivated Vaccine
    • 3.3.4: Subunit Vaccine
    • 3.3.5: Nucleic Acid Based Vaccine
  • 3.4: Global Dengue Vaccine Market by Treatment
    • 3.4.1: Diuretic
    • 3.4.2: Anti-Allergic
    • 3.4.3: Blood Thinners
    • 3.4.4: Others
  • 3.5: Global Dengue Vaccine Market by Distribution Channel
    • 3.5.1: Hospital Pharmacy
    • 3.5.2: Online Pharmacy
    • 3.5.3: Retail Pharmacy
  • 3.6: Global Dengue Vaccine Market by End Use
    • 3.6.1: Hospitals
    • 3.6.2: Homecare
    • 3.6.3: Specialty Clinics
    • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Dengue Vaccine Market by Region
  • 4.2: North American Dengue Vaccine Market
    • 4.2.1: North American Dengue Vaccine Market by Treatment: Diuretic, Anti-Allergic, Blood Thinners, and Others
    • 4.2.2: North American Dengue Vaccine Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
  • 4.3: European Dengue Vaccine Market
    • 4.3.1: European Dengue Vaccine Market by Treatment: Diuretic, Anti-Allergic, Blood Thinners, and Others
    • 4.3.2: European Dengue Vaccine Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
  • 4.4: APAC Dengue Vaccine Market
    • 4.4.1: APAC Dengue Vaccine Market by Treatment: Diuretic, Anti-Allergic, Blood Thinners, and Others
    • 4.4.2: APAC Dengue Vaccine Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
  • 4.5: ROW Dengue Vaccine Market
    • 4.5.1: ROW Dengue Vaccine Market by Treatment: Diuretic, Anti-Allergic, Blood Thinners, and Others
    • 4.5.2: ROW Dengue Vaccine Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Dengue Vaccine Market by Type
    • 6.1.2: Growth Opportunities for the Global Dengue Vaccine Market by Treatment
    • 6.1.3: Growth Opportunities for the Global Dengue Vaccine Market by Distribution Channel
    • 6.1.4: Growth Opportunities for the Global Dengue Vaccine Market by End Use
    • 6.1.5: Growth Opportunities for the Global Dengue Vaccine Market by Region
  • 6.2: Emerging Trends in the Global Dengue Vaccine Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Dengue Vaccine Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Dengue Vaccine Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Mylan
  • 7.2: BIO-MED
  • 7.3: Teva Pharmaceutical
  • 7.4: Sanofi
  • 7.5: Novartis
  • 7.6: GSK
  • 7.7: F. Hoffmann-La Roche